Links between analysis of surrogate endpoints and endogeneity

There has been substantive interest in the assessment of surrogate endpoints in medical research. These are measures that could potentially replace 'true' endpoints in clinical trials and lead to studies that require less follow-up. Recent research in the area has focused on assessments using causal inference frameworks. Beginning with a simple model for associating the surrogate and true endpoints in the population, we approach the problem as one of endogenous covariates. An instrumental variables estimator and general two-stage algorithm are proposed. Existing surrogacy frameworks are then evaluated in the context of the model. In addition, we define an extended relative effect estimator as well as a sensitivity analysis for assessing what we term the treatment instrumentality assumption. A numerical example is used to illustrate the methodology.

[1]  Vance W Berger,et al.  Does the Prentice criterion validate surrogate endpoints? , 2004, Statistics in medicine.

[2]  G. Molenberghs,et al.  The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.

[3]  Richard A. Ashley,et al.  Assessing the credibility of instrumental variables inference with imperfect instruments via sensitivity analysis , 2009 .

[4]  Jay Bhattacharya,et al.  Estimating probit models with self‐selected treatments , 2006, Statistics in medicine.

[5]  Tony Lancaster,et al.  The Econometric Analysis of Transition Data. , 1992 .

[6]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[7]  Elliott S Fisher,et al.  Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. , 2007, JAMA.

[8]  R J Carroll,et al.  On meta-analytic assessment of surrogate outcomes. , 2000, Biostatistics.

[9]  Michael R Elliott,et al.  A Bayesian Approach to Surrogacy Assessment Using Principal Stratification in Clinical Trials , 2010, Biometrics.

[10]  C. Begg,et al.  On the use of surrogate end points in randomized trials , 2000 .

[11]  G. Molenberghs,et al.  Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.

[12]  Michael G Hudgens,et al.  Evaluating Candidate Principal Surrogate Endpoints , 2008, Biometrics.

[13]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical , 2002 .

[14]  Dylan S. Small,et al.  Extended Instrumental Variables Estimation for Overall Effects , 2008, The international journal of biostatistics.

[15]  J. Pearl.  Causality: Models, Reasoning and Inference , 2000 .

[16]  D. A. Kenny,et al.  Correlation and Causation , 1937, Wilmott.

[17]  J. Hausman.  Specification tests in econometrics , 1978 .

[18]  C. Begg,et al.  On the Use of Surrogate Endpoints in Randomized Trials (with Discussion) , 2000 .

[19]  J. Robins,et al.  Identifiability and Exchangeability for Direct and Indirect Effects , 1992, Epidemiology.

[20]  D. Rubin,et al.  Principal Stratification in Causal Inference , 2002, Biometrics.

[21]  Jeremy M G Taylor,et al.  A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker , 2002, Biometrics.

[22]  Tom Greene,et al.  Related Causal Frameworks for Surrogate Outcomes , 2009, Biometrics.

[23]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[24]  Joshua D. Angrist,et al.  Identification of Causal Effects Using Instrumental Variables , 1993 .

[25]  Paul J Rathouz,et al.  Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. , 2008, Journal of health economics.

[26]  J. Angrist,et al.  Instrumental Variables Estimation of Average Treatment Effects in Econometrics and Epidemiology , 1991 .

[27]  P. Lichter,et al.  The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. , 1999, Ophthalmology.

[28]  Rodolphe Thiébaut,et al.  Counterfactual Links to the Proportion of Treatment Effect Explained by a Surrogate Marker , 2005, Biometrics.

[29]  M. Sobel.  Identification of Causal Parameters in Randomized Studies With Mediating Variables , 2008 .

[30]  M J Daniels,et al.  Meta-analysis for the evaluation of potential surrogate markers. , 1997, Statistics in medicine.

[31]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[32]  D. A. Kenny,et al.  Correlation and Causation. , 1982 .

[33]  Geert Molenberghs,et al.  Evaluation of Surrogate Endpoints , 2006, Handbook of Statistical Methods for Randomized Controlled Trials.

[34]  J. Pearl.  Causal diagrams for empirical research , 1995 .